Nicole L Davis1, Eric J Barnett2, William C Miller1, Anna Dow3, Charles S Chasela4, Michael G Hudgens5, Dumbani Kayira6, Gerald Tegha6, Sascha R Ellington7, Athena P Kourtis7, Charles van der Horst2, Denise J Jamieson7, Jonathan J Juliano2. 1. Department of Epidemiology, Gillings School of Global Public Health Division of Infectious Diseases, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill. 2. Division of Infectious Diseases, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill. 3. Department of Epidemiology, Gillings School of Global Public Health. 4. Division of Epidemiology and Biostatistics, School of Public Health, University of Witwatersrand, Parktown, South Africa. 5. Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina at Chapel Hill. 6. University of North Carolina, UNC Project, Lilongwe, Malawi. 7. Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, Georgia.
Abstract
BACKGROUND: Cotrimoxazole preventive therapy (CPT) is recommended for all human immunodeficiency virus (HIV)-exposed infants to avoid opportunistic infections. Cotrimoxazole has antimalarial effects and appears to reduce clinical malaria infections, but the impact on asymptomatic malaria infections is unknown. METHODS: We conducted an observational cohort study using data and dried blood spots (DBSs) from the Breastfeeding, Antiretrovirals and Nutrition study to evaluate the impact of CPT on malaria infection during peak malaria season in Lilongwe, Malawi. We compared malaria incidence 1 year before and after CPT implementation (292 and 682 CPT-unexposed and CPT-exposed infants, respectively), including only infants who remained HIV negative by 36 weeks of age. Malaria was defined as clinical, asymptomatic (using DBSs at 12, 24, and 36 weeks), or a composite outcome of clinical or asymptomatic. Linear and binomial regression with generalized estimating equations were used to estimate the association between CPT and malaria. Differences in characteristics of parasitemias and drug resistance polymorphisms by CPT status were also assessed in the asymptomatic infections. RESULTS: CPT was associated with a 70% (95% confidence interval, 53%-81%) relative reduction in the risk of asymptomatic infection between 6 and 36 weeks of age. CPT appeared to provide temporary protection against clinical malaria and more sustained protection against asymptomatic infections, with no difference in parasitemia characteristics. CONCLUSIONS: CPT appears to reduce overall malaria infections, with more prolonged impacts on asymptomatic infections. Asymptomatic infections are potentially important reservoirs for malaria transmission. Therefore, CPT prophylaxis may have important individual and public health benefits.
BACKGROUND:Cotrimoxazole preventive therapy (CPT) is recommended for all human immunodeficiency virus (HIV)-exposed infants to avoid opportunistic infections. Cotrimoxazole has antimalarial effects and appears to reduce clinical malaria infections, but the impact on asymptomatic malaria infections is unknown. METHODS: We conducted an observational cohort study using data and dried blood spots (DBSs) from the Breastfeeding, Antiretrovirals and Nutrition study to evaluate the impact of CPT on malaria infection during peak malaria season in Lilongwe, Malawi. We compared malaria incidence 1 year before and after CPT implementation (292 and 682 CPT-unexposed and CPT-exposed infants, respectively), including only infants who remained HIV negative by 36 weeks of age. Malaria was defined as clinical, asymptomatic (using DBSs at 12, 24, and 36 weeks), or a composite outcome of clinical or asymptomatic. Linear and binomial regression with generalized estimating equations were used to estimate the association between CPT and malaria. Differences in characteristics of parasitemias and drug resistance polymorphisms by CPT status were also assessed in the asymptomatic infections. RESULTS: CPT was associated with a 70% (95% confidence interval, 53%-81%) relative reduction in the risk of asymptomatic infection between 6 and 36 weeks of age. CPT appeared to provide temporary protection against clinical malaria and more sustained protection against asymptomatic infections, with no difference in parasitemia characteristics. CONCLUSIONS: CPT appears to reduce overall malaria infections, with more prolonged impacts on asymptomatic infections. Asymptomatic infections are potentially important reservoirs for malaria transmission. Therefore, CPT prophylaxis may have important individual and public health benefits.
Authors: Fabiana Piovesan Alves; Luiz Herman S Gil; Mauro T Marrelli; Paulo E M Ribolla; Erney P Camargo; Luiz Hildebrando Pereira Da Silva Journal: J Med Entomol Date: 2005-09 Impact factor: 2.278
Authors: Steve M Taylor; Jonathan J Juliano; Paul A Trottman; Jennifer B Griffin; Sarah H Landis; Paluku Kitsa; Antoinette K Tshefu; Steven R Meshnick Journal: J Clin Microbiol Date: 2009-11-25 Impact factor: 5.948
Authors: Steve M Taylor; Christian M Parobek; Nash Aragam; Billy E Ngasala; Andreas Mårtensson; Steven R Meshnick; Jonathan J Juliano Journal: J Infect Dis Date: 2013-08-01 Impact factor: 5.226
Authors: Charles S Chasela; Michael G Hudgens; Denise J Jamieson; Dumbani Kayira; Mina C Hosseinipour; Athena P Kourtis; Francis Martinson; Gerald Tegha; Rodney J Knight; Yusuf I Ahmed; Deborah D Kamwendo; Irving F Hoffman; Sascha R Ellington; Zebrone Kacheche; Alice Soko; Jeffrey B Wiener; Susan A Fiscus; Peter Kazembe; Innocent A Mofolo; Maggie Chigwenembe; Dorothy S Sichali; Charles M van der Horst Journal: N Engl J Med Date: 2010-06-17 Impact factor: 91.245
Authors: Nyanyiwe M Mbeye; Feiko O ter Kuile; Mary-Ann Davies; Kamija S Phiri; Matthias Egger; Gilles Wandeler Journal: Trop Med Int Health Date: 2014-07-08 Impact factor: 2.622
Authors: Moses R Kamya; Anne F Gasasira; Jane Achan; Tsedal Mebrahtu; Theodore Ruel; Adeodata Kekitiinwa; Edwin D Charlebois; Philip J Rosenthal; Diane Havlir; Grant Dorsey Journal: AIDS Date: 2007-10-01 Impact factor: 4.177
Authors: Kim A Lindblade; Laura Steinhardt; Aaron Samuels; S Patrick Kachur; Laurence Slutsker Journal: Expert Rev Anti Infect Ther Date: 2013-06 Impact factor: 5.091
Authors: Junior R Matangila; Jean Lufuluabo; Axel L Ibalanky; Raquel A Inocêncio da Luz; Pascal Lutumba; Jean-Pierre Van Geertruyden Journal: Malar J Date: 2014-04-02 Impact factor: 2.979
Authors: Khalid B Beshir; Colin J Sutherland; Patrick Sawa; Chris J Drakeley; Lucy Okell; Collins K Mweresa; Sabah A Omar; Seif A Shekalaghe; Harparkash Kaur; Arnold Ndaro; Jaffu Chilongola; Henk D F H Schallig; Robert W Sauerwein; Rachel L Hallett; Teun Bousema Journal: J Infect Dis Date: 2013-08-14 Impact factor: 5.226
Authors: Nicole L Davis; Jeffrey Wiener; Jonathan J Juliano; Linda Adair; Charles S Chasela; Dumbani Kayira; Michael G Hudgens; Charles van der Horst; Denise J Jamieson; Athena P Kourtis Journal: Clin Infect Dis Date: 2017-08-15 Impact factor: 9.079
Authors: Alexander C Ewing; Caroline C King; Jeffrey B Wiener; Charles S Chasela; Michael G Hudgens; Debbie Kamwendo; Gerald Tegha; Mina C Hosseinipour; Denise J Jamieson; Charles Van der Horst; Athena P Kourtis Journal: AIDS Date: 2017-11-28 Impact factor: 4.177
Authors: Shahin Lockman; Michael Hughes; Kate Powis; Gbolahan Ajibola; Kara Bennett; Sikhulile Moyo; Erik van Widenfelt; Jean Leidner; Kenneth McIntosh; Loeto Mazhani; Joseph Makhema; Max Essex; Roger Shapiro Journal: Lancet Glob Health Date: 2017-05 Impact factor: 26.763
Authors: Zaneta D Musimbi; Martin K Rono; James R Otieno; Nelson Kibinge; Lynette Isabella Ochola-Oyier; Etienne Pierre de Villiers; Eunice W Nduati Journal: Sci Rep Date: 2019-12-02 Impact factor: 4.379
Authors: Herbert Longwe; Kamija S Phiri; Nyanyiwe M Mbeye; Thandile Gondwe; Wilson L Mandala; Kondwani C Jambo Journal: Malar J Date: 2016-05-10 Impact factor: 2.979
Authors: Anna Babakhanyan; Gabriel Loni Ekali; Arlene Dent; James Kazura; John Tamo Nguasong; Barriere Airy Yetgang Fodjo; Emile Keming Yuosembom; Livo Forgu Esemu; Diane Wallace Taylor; Rose Gana Fomban Leke Journal: Open Forum Infect Dis Date: 2016-05-10 Impact factor: 3.835
Authors: Alexander C Ewing; Nicole L Davis; Dumbani Kayira; Mina C Hosseinipour; Charles van der Horst; Denise J Jamieson; Athena P Kourtis Journal: Emerg Infect Dis Date: 2019-01 Impact factor: 6.883
Authors: Abel Kakuru; Paul Natureeba; Mary K Muhindo; Tamara D Clark; Diane V Havlir; Deborah Cohan; Grant Dorsey; Moses R Kamya; Theodore Ruel Journal: Malar J Date: 2016-10-18 Impact factor: 2.979
Authors: Kathleen M Powis; Sajini Souda; Shahin Lockman; Gbolahan Ajibola; Kara Bennett; Jean Leidner; Michael D Hughes; Sikhulile Moyo; Erik van Widenfelt; Haruna B Jibril; Joseph Makhema; Max Essex; Roger L Shapiro Journal: J Int AIDS Soc Date: 2017-11 Impact factor: 5.396